CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 68 enrolled
Drug / intervention
HZ/su vaccine (GSK1437173A)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04176939
NCT04176939Phase 3Completed
CompareCT.gov

Long-term Immunogenicity Study of Herpes Zoster Subunit Vaccine (GSK1437173A) and Immunogenicity and Safety Assessment of Revaccination With Two Additional Doses in Adults With Renal Transplant From Study ZOSTER-041

GlaxoSmithKline·interventional·Posted Nov 25, 2019·Updated Jul 18, 2025

In Brief

A Phase 3 clinical trial evaluating HZ/su vaccine (GSK1437173A) for Herpes Zoster. Completed, enrolled 68 participants across 15 sites in 7 countries.

Detailed Summary

The purpose of this study was to evaluate the long-term immune responses to the Herpes Zoster subunit (HZ/su) vaccine as well as safety up to 7 years after the 2-dose primary vaccination course from study ZOSTER-041 (NCT02058589). This study also assessed immune responses as well as safety after revaccination with 2 additional doses of the HZ/su administered at 6 to 8 years after the 2-dose primary vaccination course.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesBelgium, Canada, Finland, Panama, South Korea, Spain, Taiwan
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedNov 25, 2019
Enrollment StartDec 9, 2019
Primary CompletionAug 12, 2022
Study CompletionJun 27, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.6 years ago

Interventions

HZ/su vaccine (GSK1437173A)biological

2 intramuscular (IM) revaccination doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.